- Home
- PBM
as 07-05-2024 1:37pm EST
Stocks
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed ISO22000 facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
| Founded: | 1994 | Country: | Ontario, Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 4.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 788.2K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.27 - $14.55 | Next Earning Date: | 08-02-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PSYENCE BIOMEDICAL LTD News
PBM Breaking Stock News: Dive into PBM Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
GlobeNewswire
2 months ago
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
GlobeNewswire
3 months ago
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
GlobeNewswire
3 months ago
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
GlobeNewswire
3 months ago
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
GlobeNewswire
3 months ago
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
GlobeNewswire
4 months ago
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
GlobeNewswire
4 months ago
Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares
Share on Social Networks:
Disclaimer
The information presented on this page, "PBM PSYENCE BIOMEDICAL LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.